Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06130579
Status:
RECRUITING
Last Update Posted:
2024-03-21
First Post:
2023-11-08
Brief Title:
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
Interferon-α for Preventing Relapse in TP53 Myeloid Malignancy Post Allo-HSCT
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia AML and myelodysplastic syndrome MDS with TP53 mutation who were negative for minimal residual disease MRD by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation To explore the efficacy of interferon-α in reducing the relapse rate of AMLMDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation allo-HSCT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None